Intensity Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Intensity Therapeutics is a pre-commercial clinical-stage biotechnology company developing INT230-6, an intratumoral formulation of cisplatin, vinblastine sulfate and the diffusion enhancer SHAO. It reported no product or licensing revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.786 million | $5.132 million |
| General and administrative expense | $3.533 million | $2.418 million |
| Total operating expenses / loss from operations | $8.319 million | $7.550 million |
| Net loss | $10.538 million | $7.582 million |
| Net loss attributable to common stockholders | $11.862 million | $7.582 million |
| Basic and diluted loss per share | $1.38 | $2.22 |
| Net cash used in operating activities | $7.205 million | $5.477 million |
The difference between 2023 net loss and loss attributable to common stockholders reflects a $1.324 million preferred-stock deemed dividend. Operating margins are not meaningful because the company had no revenue.
At December 31, 2023, cash and cash equivalents were $8.556 million and marketable U.S. Treasury bills were $6.220 million, totaling $14.776 million. Current assets were $15.464 million, current liabilities $3.959 million, total liabilities $4.133 million and stockholders’ equity $13.162 million. The company reported no convertible notes or other debt outstanding at year-end; pre-IPO convertible notes and accrued interest converted into common stock.
Cash provided by financing activities was $20.472 million, principally from the 2023 IPO; investing activities used $6.023 million, primarily for net purchases of Treasury bills. Management estimated that year-end cash and investments would fund the current operating plan through the end of the first quarter of 2025. The auditor’s report and management both disclosed substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and negative operating cash flows.
Material changes and unusual items
- Net loss increased by $2.956 million year over year. R&D expense declined by $0.346 million as IT-01 enrollment ended, partly offset by preparatory work for the planned sarcoma trial and higher manufacturing costs. G&A rose by $1.115 million, including higher public-company insurance, compensation and stock-based compensation costs.
- The company recorded a $2.262 million loss on debt extinguishment associated with conversion of notes at the IPO and a $1.324 million preferred-stock deemed dividend related to anti-dilution provisions. Interest income rose to $0.324 million following the IPO; interest expense was $0.305 million.
- The June–July 2023 IPO and full exercise of the over-allotment option issued 4.485 million shares at $5.00 per share, generating $22.425 million gross proceeds and approximately $20.2 million net proceeds. Common shares outstanding were 13,709,377 at year-end.
Clinical progress, outlook and key risks
- IT-01, a 110-patient Phase 1/2 study in refractory or metastatic cancers, completed enrollment in 2022; its database was locked and the clinical study report finalized in 2023. The company reported a favorable safety profile, with 15 of 110 patients experiencing at least one treatment-related grade 3 adverse event, one grade 4 event and no grade 5 treatment-related events. These results are from an early-stage study without a randomized control arm.
- In the 91-patient presurgical breast cancer INVINCIBLE-2 study, the company reported mean tumor necrosis of 19% in the treatment group versus 1.3% with saline control (p=0.0002). It also reported immune-cell and T-cell repertoire changes. These findings are not evidence of regulatory approval or established clinical benefit.
- Exploratory IT-01 sarcoma survival comparisons included small patient groups and historical or synthetic controls. The filing reports median overall survival of about 21 months for the 15 monotherapy sarcoma patients versus a 6.7-month synthetic historical estimate; the company cautions that the comparison is limited and not a randomized efficacy test.
- The company planned to start a randomized Phase 3 study in selected soft-tissue sarcomas, targeting 333 patients and overall survival as the primary endpoint, and a Phase 2/3 presurgical breast cancer program, with initiation planned for mid-2024. A separate metastatic triple-negative breast cancer program is contingent on additional capital. These are forward-looking plans, not completed milestones.
- The FDA issued a “Study May Proceed” letter for the proposed sarcoma Phase 3 trial and agreed with the company on a CMC plan. The company also reported orphan drug designation for INT230-6 components in soft-tissue sarcoma and Fast Track designation for metastatic triple-negative breast cancer. Neither designation guarantees approval.
- Funding remains a central risk: the company has no committed external funding and expects to need additional capital. Financing may dilute shareholders or require less favorable terms, and insufficient funds could delay or curtail development programs.
- Disclosure controls were deemed ineffective at year-end due to material weaknesses in segregation of duties, review of clinical contract accruals and IT user-access controls. Remediation was underway; the company said it could not assure full remediation. It also disclosed that it had not adopted a formal cybersecurity risk management program.
Important facts for investors to verify
- Whether cash, investments and any subsequent financing are sufficient to support the planned trials, and whether the stated runway remains current.
- Actual initiation, enrollment, protocol and funding status of the sarcoma and breast cancer programs; the filing describes maintenance dosing at both 9-week and 12-week intervals for the sarcoma study, so the final protocol should be checked.
- Full clinical datasets, statistical analyses, safety follow-up and limitations of the uncontrolled or historical-control comparisons, including the exploratory sarcoma survival claims.
- Progress against internal-control remediation and any subsequent changes in financial reporting controls.
- Potential dilution from future equity issuance and outstanding options and warrants; the filing reports 13.7 million common shares outstanding at year-end and additional equity awards available under the incentive plan.